Aldeyra Therapeutics (NASDAQ:ALDX) Rating Reiterated by HC Wainwright

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. They presently have a $10.00 target price on the biotechnology company's stock. HC Wainwright's price target would suggest a potential upside of 181.69% from the company's current price.

Separately, StockNews.com upgraded shares of Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, January 29th.

Aldeyra Therapeutics Trading Up 8.6 %

NASDAQ ALDX opened at $3.55 on Tuesday. Aldeyra Therapeutics has a 1-year low of $1.42 and a 1-year high of $11.97. The company has a 50 day moving average of $3.31 and a 200-day moving average of $3.41. The company has a market cap of $209.10 million, a price-to-earnings ratio of -5.55 and a beta of 1.51.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.13. On average, equities research analysts forecast that Aldeyra Therapeutics will post -0.26 earnings per share for the current year.

Insiders Place Their Bets

In other Aldeyra Therapeutics news, CEO Todd C. Brady sold 97,914 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $3.27, for a total transaction of $320,178.78. Following the sale, the chief executive officer now owns 1,556,622 shares of the company's stock, valued at $5,090,153.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Aldeyra Therapeutics news, insider Bruce Greenberg sold 13,201 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $3.41, for a total transaction of $45,015.41. Following the sale, the insider now owns 120,699 shares of the company's stock, valued at $411,583.59. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Todd C. Brady sold 97,914 shares of the business's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.27, for a total transaction of $320,178.78. Following the sale, the chief executive officer now directly owns 1,556,622 shares in the company, valued at approximately $5,090,153.94. The disclosure for this sale can be found here. Insiders own 7.30% of the company's stock.

Institutional Trading of Aldeyra Therapeutics

Several institutional investors have recently modified their holdings of ALDX. JPMorgan Chase & Co. grew its stake in shares of Aldeyra Therapeutics by 21.3% in the first quarter. JPMorgan Chase & Co. now owns 22,835 shares of the biotechnology company's stock worth $101,000 after purchasing an additional 4,012 shares during the last quarter. Raymond James & Associates grew its stake in shares of Aldeyra Therapeutics by 21.2% in the first quarter. Raymond James & Associates now owns 26,306 shares of the biotechnology company's stock worth $117,000 after purchasing an additional 4,609 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Aldeyra Therapeutics by 12.2% in the first quarter. Bank of New York Mellon Corp now owns 209,815 shares of the biotechnology company's stock worth $932,000 after purchasing an additional 22,748 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Aldeyra Therapeutics by 11.7% in the first quarter. Rhumbline Advisers now owns 47,596 shares of the biotechnology company's stock worth $212,000 after purchasing an additional 4,996 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Aldeyra Therapeutics by 5.2% in the first quarter. Vanguard Group Inc. now owns 2,961,635 shares of the biotechnology company's stock worth $13,165,000 after purchasing an additional 147,711 shares during the last quarter. Institutional investors own 59.71% of the company's stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.